Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Y 3

Next Previous
Drug Profile

Y 3

Alternative Names: Y-3

Latest Information Update: 15 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroDawn
  • Developer China Medical System; NeuroDawn
  • Class Antidepressants; Small molecules; Vascular disorder therapies
  • Mechanism of Action GABA A alpha 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ischaemic stroke
  • Phase I Stroke

Most Recent Events

  • 10 Jul 2025 Neurodawn Pharmaceuticals plans a phase I pharmacokinetics trial in July 2025 (IV) (NCT07055412)
  • 18 May 2025 Neurodawn Pharmaceutical initiates enrolment in the phase I pharmacokinetics trial (In volunteers) in China (IV) (NCT07068841)
  • 06 Jan 2025 Phase-I clinical trials in Stroke (In volunteers) in USA (IV) (NCT06770491)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top